Clinical trials are a strong bottleneck in the drug development process due to high cost & high failure rate. To prevent high failure cost, our customers and partner have decided to invest in better early stage preclinical model mimicking in vitro human patho-physiology.
Cherry Biotech has developed a patented integrated platform allowing an in vitro early-stage toxicity and efficacy detection dedicated to type 2 diabetes drug development. We mimicking human physiology, by recapitulating human differentiated endothelium to vascularize an adipose tissue in a 3D in vitro microsystem.
Cherry Biotech intends to become a global innovation leader by providing in-vitro platform as an alternative to animal model for preclinical drug development for any indication/disease.